Genentech

March 7, 2016

Last Week’s Hot Topic on Lymphoma

Last week’s hot topic on Lymphoma was about the FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan written by Carolina Henriques. The article is centered around Genentech‘s announcement that the U.S. ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more

November 16, 2015

Last Week’s Top-3 Most Read Posts On Lymphoma

Read the Articles Here: Reasons to Participate in a Lymphoma Clinical Trial Hodgkin’s Lymphoma Patient Responds Well to Off-label Therapy with Nivolumab Genentech’s Lymphoma Trial Results to Be Key Focus ... Read more

November 9, 2015May 13, 2016

Genentech’s Lymphoma Trial Results to Be Key Focus of ASH Meeting

News

Genentech recently announced that more than 45 abstracts, including eight of its approved or investigational medicines, will be presented during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, set ... Read more

September 1, 2015September 1, 2015

Phase II Study of Investigational Medicine Venetoclax Meets Primary Endpoint With Positive Results

News

Genentech in partnership with AbbVie Pharmaceuticals and the Leukemia & Lymphoma Society (LLS), recently announced positive results from a Phase 1 clinical trial for venetoclax, an investigational therapy to treat patients with ... Read more

June 2, 2015August 23, 2016

Genentech’s Therapeutic Strategy for Indolent Non-Hodgkin’s Lymphoma Improves Patients’ Survival

News

Genentech, a member of the Roche Group focused on the treatment of serious or life-threatening medical conditions, recently announced new data on their Phase III GADOLIN trial (NCT01059630) on the ... Read more